ストックスクリーナーアプリを入手
8.56
1.30%
0.11
前日終値:
$8.45
開ける：
$8.6
24時間の取引高:
348.03K
Relative Volume:
0.35
時価総額：
$192.97M
収益：
$146.07M
当期純損益:
$-196.04M
株価収益率:
-0.515
EPS:
-16.621
ネットキャッシュフロー:
$-75.37M
1週間 パフォーマンス:
+18.07%
1か月 パフォーマンス:
+9.04%
6か月 パフォーマンス:
+43.87%
1年 パフォーマンス:
+100.94%
1日の値動き範囲:
$8.40
$8.81
1週間の範囲:
$7.19
$8.87
52週間の値動き範囲:
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
名前
Karyopharm Therapeutics Inc
セクター
電話
617-658-0600
住所
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.56 | 190.49M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Rodman & Renshaw | Buy |
| 2026-02-05 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-10-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 再開されました | H.C. Wainwright | Buy |
| 2023-01-19 | 開始されました | Piper Sandler | Overweight |
| 2022-11-04 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-08-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 開始されました | Morgan Stanley | Overweight |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-07-23 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-05 | 繰り返されました | Robert W. Baird | Outperform |
| 2019-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 開始されました | B. Riley FBR | Buy |
| 2018-11-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2018-05-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-04-02 | 再開されました | Leerink Partners | Outperform |
| 2017-11-15 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2016-09-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-30 | アップグレード | Jefferies | Hold → Buy |
| 2016-08-18 | 開始されました | H.C. Wainwright | Buy |
| 2016-06-28 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Karyopharm Therapeutics Inc (KPTI) 最新ニュース
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
Karyopharm Therapeutics (KPTI) affiliated managers report 1.9%–2.3% stakes - Stock Titan
[ARS] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan
Karyopharm (KPTI) seeks approval for director slate and larger equity plans - Stock Titan
Gains Report: Can Karyopharm Therapeutics Inc disrupt its industry2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | KPTI Stock News - GuruFocus
Portfolio Update: Will Karyopharm Therapeutics Inc stock benefit from M A2026 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Quarterly Earnings: How sensitive is Karyopharm Therapeutics Inc to inflationPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating - Moomoo
Dip Buying: Is Karyopharm Therapeutics Inc attractive for institutional investors2026 Update & Growth Oriented Trading Recommendations - baoquankhu1.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
RA Capital (NASDAQ: KPTI) and partners report 9.99% stake in Karyopharm - Stock Titan
Commodore Group discloses 1.95M KPTI stake; 19,618,032 shares O/S - Stock Titan
Karyopharm Therapeutics Inc. R (25K0.DU) insider ownership and holdings - Yahoo Finance Australia
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Up 20.9% in March - MarketBeat
Will Karyopharm Therapeutics Inc benefit from green energy policiesInsider Buying & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Piper Sandler Lowers Price Target for Karyopharm Therapeutics (K - gurufocus.com
Piper Sandler Reaffirms "Overweight" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm stock price target cut to $8 by Piper Sandler on trial results - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - benzinga.com
Karyopharm Strengthens Liquidity With New Equity Financing - tipranks.com
Karyopharm Therapeutics raises $30 million in private placement with RA Capital - Investing.com Australia
Karyopharm Therapeutics raises $30 million in private placement with RA Capital By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar? - Yahoo Finance
HC Wainwright Has Optimistic Outlook of KPTI Q1 Earnings - MarketBeat
Karyopharm Therapeutics raises ~$30M in private placement, adds ~$19.8M via ATM - TradingView
Karyopharm (NASDAQ: KPTI) completes $30M private placement and ATM sale - Stock Titan
Karyopharm: Putting The Phase 3 Trial In Context (NASDAQ:KPTI) - Seeking Alpha
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo Finance
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Karyopharm Therapeutics falls as pivotal trial hits spleen goal but misses symptom mark - msn.com
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - ca.investing.com
Karyopharm Therapeutics Inc (KPTI) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):